Michael Pfreundschuh

Summary

Affiliation: Saarland University
Country: Germany

Publications

  1. pmc MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians
    Joerg Bittenbring
    Internal Medicine I and José Carreras Research Center, University of Saarland Medical School, Homburg Saar, Germany
    BMC Cancer 8:116. 2008
  2. pmc Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study
    Gunter Assmann
    Department of Rheumatology, University Saarland Medical School Kirrbergerstrasse 1, D66421 Homburg, Germany
    Arthritis Res Ther 11:R140. 2009
  3. ncbi request reprint CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    University Clinic of Saarland, Homburg, Germany
    Lancet Oncol 7:379-91. 2006
  4. doi request reprint CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    Universitatsklinikum des Saarlandes, Homburg, Germany
    Lancet Oncol 12:1013-22. 2011
  5. doi request reprint Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group
    Michael Pfreundschuh
    Saarland University Medical School, Homburg, Germany
    Lancet Oncol 9:435-44. 2008
  6. doi request reprint Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
    Michael Pfreundschuh
    Internal Medicine, Saarland University Medical School, Saarland University, Homburg, Germany
    Lancet Oncol 9:105-16. 2008
  7. pmc The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab
    Manfred Ahlgrimm
    Saarland University Medical School, Homburg, Germany
    Blood 118:4657-62. 2011
  8. ncbi request reprint Sustained telomere erosion due to increased stem cell turnover during triple autologous hematopoietic stem cell transplantation
    Thomas Widmann
    Klinik und Poliklinik für Innere Medizin I, Universitätsklinikum Homburg, Homburg, Germany
    Exp Hematol 36:104-10. 2008
  9. doi request reprint Rituximab in high-grade lymphoma
    Carsten Zwick
    Innere Medizin I, Saarland University Medical School, Homburg, Germany
    Semin Hematol 47:148-55. 2010
  10. doi request reprint Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP r
    Carsten Zwick
    Innere Medizin I, Universitatskliniken des Saarlandes, Homburg, Germany
    Ann Hematol 87:717-26. 2008

Detail Information

Publications76

  1. pmc MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians
    Joerg Bittenbring
    Internal Medicine I and José Carreras Research Center, University of Saarland Medical School, Homburg Saar, Germany
    BMC Cancer 8:116. 2008
    ..Here we asked whether SNP309 and SNP72 are associated with DLBCL in women and are correlated with age of onset, diagnosis, or patient's survival...
  2. pmc Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study
    Gunter Assmann
    Department of Rheumatology, University Saarland Medical School Kirrbergerstrasse 1, D66421 Homburg, Germany
    Arthritis Res Ther 11:R140. 2009
    ..The etiology of SAPHO syndrome is unknown, but an association with infection by semipathogenic bacteria like Propionibacterium acnes has been suggested. We conducted an interventional study of SAPHO patients receiving antibiotics...
  3. ncbi request reprint CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    University Clinic of Saarland, Homburg, Germany
    Lancet Oncol 7:379-91. 2006
    ..We aimed to compare CHOP-like chemotherapy and rituximab with CHOP-like chemotherapy alone in these patients...
  4. doi request reprint CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    Universitatsklinikum des Saarlandes, Homburg, Germany
    Lancet Oncol 12:1013-22. 2011
    ..Extended follow-up was needed to establish long-term effects...
  5. doi request reprint Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group
    Michael Pfreundschuh
    Saarland University Medical School, Homburg, Germany
    Lancet Oncol 9:435-44. 2008
    ..We aimed to assess the effect of maximum tumour diameter (MTD) in these patients...
  6. doi request reprint Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
    Michael Pfreundschuh
    Internal Medicine, Saarland University Medical School, Saarland University, Homburg, Germany
    Lancet Oncol 9:105-16. 2008
    ..This randomised trial assessed whether six or eight cycles of R-CHOP-14 can improve outcome of these patients compared with six or eight cycles of CHOP-14...
  7. pmc The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab
    Manfred Ahlgrimm
    Saarland University Medical School, Homburg, Germany
    Blood 118:4657-62. 2011
    ..052) for PFS and 1.55 (P = .120) for EFS. The interaction of R-CHOP, but not CHOP with FcγRIIIa polymorphisms, indicates a window of opportunity for CD20 antibodies designed to mediate enhanced antibody-dependent cellular cytotoxicity...
  8. ncbi request reprint Sustained telomere erosion due to increased stem cell turnover during triple autologous hematopoietic stem cell transplantation
    Thomas Widmann
    Klinik und Poliklinik für Innere Medizin I, Universitätsklinikum Homburg, Homburg, Germany
    Exp Hematol 36:104-10. 2008
    ..We observed sustained telomere shortening in hematopoietic cells after triple stem cell transplantation with prolonged stem cell replication during the first year after stem cell transplantation...
  9. doi request reprint Rituximab in high-grade lymphoma
    Carsten Zwick
    Innere Medizin I, Saarland University Medical School, Homburg, Germany
    Semin Hematol 47:148-55. 2010
    ..For these patients new modalities of second-line therapy are urgently warranted...
  10. doi request reprint Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP r
    Carsten Zwick
    Innere Medizin I, Universitatskliniken des Saarlandes, Homburg, Germany
    Ann Hematol 87:717-26. 2008
    ....
  11. ncbi request reprint Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas
    Gerhard Held
    Innere Medizin I, Saarland University Medical School, Homburg, Germany
    Semin Hematol 43:221-9. 2006
    ..Finally, the issue of intensifying rituximab within such approaches must be addressed by appropriately designed randomized trials...
  12. doi request reprint EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors
    Frank Neumann
    Department of Internal Medicine I, José Carreras Center for Immuno and Gene Therapy, University of Saarland Medical School, 66421, Homburg, Saar, Germany
    Cancer Immunol Immunother 62:1211-22. 2013
    ..The stability of the CT gene expression over prolonged culture periods makes LCL attractive candidates for CT vaccines both in hematological neoplasias and solid tumors...
  13. doi request reprint Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigens
    Carsten Zwick
    Jose Carreras Center, Saarland University Medical School, Homburg, Saar, Germany
    Ann Hematol 88:999-1003. 2009
    ....
  14. doi request reprint New drugs for aggressive B-cell and T-cell lymphomas
    Niels Murawski
    Saarland University Medical School, Homburg, Germany
    Lancet Oncol 11:1074-85. 2010
    ..The definition of the role of these new drugs alone or in combination with established chemotherapy regimens in adequately designed prospective trials represents one of the major challenges in clinical lymphoma research...
  15. ncbi request reprint MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing
    Gerhard Held
    I Med Klinik, Saarland University Medical School, Homburg Saar, Germany
    Eur J Immunol 37:2008-17. 2007
    ....
  16. ncbi request reprint Rituximab for the treatment of diffuse large B-cell lymphomas
    Gerhard Held
    Klinik fur Innere Medizin I, Saarland University Medical School, D 66421 Homburg, Saar, Germany
    Expert Rev Anticancer Ther 6:1175-86. 2006
    ..Its excellent efficacy in combination with cytotoxic chemotherapy, together with its favorable toxicity profile, establishes rituximab as an indispensable component of modern standard immunochemotherapy of DLBCL...
  17. ncbi request reprint Analysis of the B-cell repertoire against antigens expressed by human neoplasms
    Klaus Dieter Preuss
    Saarland University Medical School, Homburg, Germany
    Immunol Rev 188:43-50. 2002
    ..Novel strategies are necessary to identify antigens that can serve as a vaccine target in a broad spectrum of non-Hodgkin's lymphoma patients...
  18. doi request reprint Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomas
    Carsten Zwick
    Innere Medizin I, Jose Carreras Center for Immuno and Genetherapy, Saarland University Medical School Homburg, 66421 Homburg, Saar, Germany
    J Cancer Res Clin Oncol 135:1207-13. 2009
    ..Molecules which are exclusively or preferentially expressed by malignant cells are potential targets for immunotherapeutic approaches to the treatment of cancer...
  19. doi request reprint Notch- and vitamin D signaling in 1,25(OH)2D3-resistant glioblastoma multiforme (GBM) cell lines
    Sandra Reichrath
    Department of Internal Medicine I, The Saarland University Hospital, Homburg Saar, Germany
    J Steroid Biochem Mol Biol 121:420-4. 2010
    ..Our findings do not support the hypothesis that modulation of Notch-signaling pathways by 1,25(OH)2D3 may regulate growth of GBM cell lines...
  20. ncbi request reprint Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers
    Gunter Assmann
    Internal Medicine I and José Carreras Research Centre, University of Saarland Medical School, Homburg Saar, Germany
    Clin Exp Rheumatol 28:81-3. 2010
    ..To test the efficacy of treatment with rituximab in refractory rheumatoid vasculitis in patients with rheumatoid arthritis (RA)...
  21. doi request reprint Genetic variations in genes encoding RANK, RANKL, and OPG in rheumatoid arthritis: a case-control study
    Gunter Assmann
    Internal Medicine I and José Carreras Research Centre, University of Saarland Medical School, Homburg Saar, Germany
    J Rheumatol 37:900-4. 2010
    ..Genetic variations in the genes coding for RANK, RANK ligand (RANKL), and OPG are thought to play roles in the susceptibility to RA...
  22. doi request reprint Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome
    Gunter Assmann
    Internal Medicine I, Oncology and Rheumatology and José Carreras Research Center, University of Saarland Medical School, 66421, Homburg Saar, Germany
    Rheumatol Int 30:1273-6. 2010
    ..In contrast, the p53 network does not seem to play a major role in pathogenesis of Ps or PsA...
  23. ncbi request reprint Factors predictive for response of follicular and mantle-cell lymphoma to rituximab
    Michael Pfreundschuh
    Internal Medicine at Saarland University Medical School, Homburg, Germany
    Nat Clin Pract Oncol 3:184-5. 2006
  24. doi request reprint Desmoplakin and KIF20B as target antigens in patients with paroxysmal nocturnal haemoglobinuria
    Adnan Alahmad
    Jose Carrerase Center for Immuno and Genetherapy, Department of Internal Medicine Ι, Saarland University Medical School, Homburg, Germany
    Br J Haematol 151:273-80. 2010
    ..The analysis of the mechanisms underlying the autoimmune response might contribute to our understanding of the clonal expansion in PNH...
  25. ncbi request reprint Expression of serologically identified tumor antigens in acute leukemias
    Philipp Niemeyer
    Department of Internal Medicine, Saarland University, D 66424, Saar, Homburg, Germany
    Leuk Res 27:655-60. 2003
    ..However, the identification of additional antigens with a frequent expression in leukemias is warranted to allow the development of widely applicable polyvalent leukemia vaccines...
  26. ncbi request reprint Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2
    Frank Neumann
    Medizinische Klinik I, Saarland University Medical School, Homburg, Germany
    Int J Cancer 112:661-8. 2004
    ..p45-59 holds promise as a broadly applicable peptide vaccine for patients with SSX2-positive neoplasms...
  27. ncbi request reprint Characterization of Hap/BAG-1 variants as RP1 binding proteins with antiapoptotic activity
    Andreas Wadle
    Med Department I, Saarland University Medical School, Homburg, Germany
    Int J Cancer 117:896-904. 2005
    ..Subcellular distribution analysis revealed that the Hap/Bag-1 variant protein localized homogenously to the cytoplasm and shuttles into the nucleus in response to stress, a process that could be blocked by RP1 protein overexpression...
  28. ncbi request reprint Successful treatment of disseminated aspergillosis with the combination of voriconazole, caspofungin, granulocyte transfusions, and surgery followed by allogeneic blood stem cell transplantation in a patient with primary failure of an autologous stem cell
    Robert Dinser
    Medizinische Klinik I, Universitatsklinikum des Saarlandes, Homburg, Germany
    Eur J Haematol 74:438-41. 2005
    ..The patient is well and free of clinical disease with respect to the fungal infection and myeloma more than 18 months after the allogeneic transplantation...
  29. ncbi request reprint Hodgkin and Reed-Sternberg cell-associated autoantigen CLIP-170/restin is a marker for dendritic cells and is involved in the trafficking of macropinosomes to the cytoskeleton, supporting a function-based concept of Hodgkin and Reed-Sternberg cells
    Ugur Sahin
    Medizinische Klinik I, Saarland University Medical School, Homburg, Germany
    Blood 100:4139-45. 2002
    ..The strong expression of CLIP-170/restin in HRS cells, DCs, and activated B cells underscores their functional similarities supporting a function-based concept of HRS cells as professional antigen-presenting cells...
  30. ncbi request reprint Short telomeres in aggressive non-Hodgkin's lymphoma as a risk factor in lymphomagenesis
    Thomas A Widmann
    Klinik und Poliklinik für Innere Medizin I, Universitätsklinikum Homburg, Homburg, Germany
    Exp Hematol 35:939-46. 2007
    ..It has not been systematically studied whether patients with malignancy have shortened telomeres in their normal, nontransformed cells, which might point to a preexisting disposition for chromosomal instability...
  31. pmc Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation
    Thomas Widmann
    Department of Internal Medicine I, University Clinics of the Saarland, Homburg, Germany
    PLoS ONE 3:e3634. 2008
    ..In conclusion, levels of CMV-specific CD4 T cells inversely correlate with reactivation episodes and may represent a valuable measure to individually guide antiviral therapy after stem cell transplantation...
  32. ncbi request reprint Mature T-cell and NK/T-cell neoplasms
    Michael Pfreundschuh
    University of Saarland, Homburg, Germany
    Clin Adv Hematol Oncol 3:suppl 8-9. 2005
  33. ncbi request reprint Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas
    Rudolf Schmits
    Department of Medicine, Saarland University Medical School, Homburg, Germany
    Int J Cancer 98:73-7. 2002
    ..We conclude that although astrocytomas express a broad spectrum of antigens, they elicit antibody responses only rarely, most likely because of their intrinsic immunosuppressive effects...
  34. ncbi request reprint Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma
    Maha Ayyoub
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland
    J Immunol 168:1717-22. 2002
    ....
  35. ncbi request reprint Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments
    Gerhard Held
    Clinic for Internal Medicine I, Saarland University Medical School, Homburg Saar, Germany
    Eur J Immunol 34:2919-29. 2004
    ..It may therefore become a useful monitoring tool for the development of NY-ESO-1-based cancer vaccines...
  36. ncbi request reprint A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
    Eva Hoster
    Department of Internal Medicine III, University of Munich, Germany
    Blood 111:558-65. 2008
    ..The MIPI is the first prognostic index particularly suited for MCL patients and may serve as an important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL...
  37. ncbi request reprint Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL
    Michael Pfreundschuh
    Saarland University Medical School, Homburg Saar, Germany
    Blood 104:634-41. 2004
    ..Due to its favorable efficacy and toxicity profile, CHOP-14 should be considered the new standard chemotherapy regimen for patients ages 60 or older with aggressive lymphoma...
  38. ncbi request reprint Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma
    Carsten Zwick
    Klinik fur Innere Medizin I, Saarland University Medical School, Homburg Saar, Germany
    Clin Lymphoma Myeloma 8:S43-9. 2007
    ..The optimal dose and schedule of rituximab has yet to be determined. Aspects of supportive measures meant to ensure optimal adherence to dose-dense regimens are discussed herein...
  39. ncbi request reprint Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL
    Michael Pfreundschuh
    Saarland University Medical School, Homburg Saar, Germany
    Blood 104:626-33. 2004
    ..Although the CHOEP regimens induced more myelosuppression, all regimens were well tolerated. CHOEP should be the preferred chemotherapy regimen for young patients with good-prognosis (normal LDH level) aggressive lymphoma...
  40. doi request reprint Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells
    Gerhard Held
    Jose Carreras Center for Immuno and Genetherapy, Klinik fur Innere Medizin I, Saarland University Medical School, 66421 Homburg, Saar, Germany
    Int J Cancer 123:1841-7. 2008
    ..MHC-peptide specific antibodies are a valuable tool for the analysis of antigenic peptides in the context of MHC-I molecules and for the structural definition of immunodominant epitopes...
  41. ncbi request reprint Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2
    Claudia Wagner
    Med Klinik I, Saarland University Medical School, D 66424 Homburg, Germany
    Cancer Immun 3:18. 2003
    ..p103-111 holds promise as a broadly applicable peptide vaccine for patients with HOM-MEL-40/SSX2 positive neoplasms...
  42. ncbi request reprint Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients
    Axel Mischo
    I Med Klinik, Saarland University Medical School, Homburg Saar, Germany
    Cancer Immun 3:5. 2003
    ....
  43. ncbi request reprint Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
    Volker Diehl
    First Department of Internal Medicine, University of Cologne, Cologne, Germany
    N Engl J Med 348:2386-95. 2003
    ..Faced with unsatisfactory results of treatment for advanced Hodgkin's disease, we investigated three combinations of chemotherapy...
  44. ncbi request reprint Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5
    Markus Sieber
    German Hodgkin s Lymphoma Study Group, Cologne, Germany
    J Clin Oncol 20:476-84. 2002
    ....
  45. ncbi request reprint Aggressive lymphoma: improving treatment outcome with rituximab
    Bertrand Coiffier
    Hospices Civils de Lyon, Lyon, France
    Anticancer Drugs 13:S43-50. 2002
    ....
  46. ncbi request reprint Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma
    Ulrich Kaiser
    Department of Hematology, Universitätsklinikum Marburg, Germany
    J Clin Oncol 20:4413-9. 2002
    ....
  47. ncbi request reprint Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model
    Boris Kubuschok
    Department of Internal Medicine I, University of Saarland Medical School, D 66421 Homburg Saar, Germany
    Hum Gene Ther 13:815-27. 2002
    ..We conclude that genetically modified muRas-LCLs can efficiently present tumor antigens to the immune system and induce antigen-specific cytotoxic T cell responses in vitro and in vivo...
  48. ncbi request reprint Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial
    Andreas Engert
    First Department of Internal Medicine, Coordination Center for Clinical Trials, and Department of Radiotherapy, University Hospital of Cologne, Cologne, Germany
    J Clin Oncol 25:3495-502. 2007
    ....
  49. ncbi request reprint NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity
    Leszek Wojnowski
    Department of Pharmacology, University Mainz, D 55101 Mainz, Germany
    Circulation 112:3754-62. 2005
    ..There are no data on pharmacogenomic predictors of ACT...
  50. ncbi request reprint The best treatment for diffuse large B-cell lymphoma: a German perspective
    Rudolf Schmits
    German High Grade Non Hodgkin s Lymphoma Study Group DSHNHL, Homburg Saar Germany
    Oncology (Williston Park) 19:16-25. 2005
    ....
  51. ncbi request reprint Influence of telomere length on short-term recovery after allogeneic stem cell transplantation
    Thomas Alexander Widmann
    Saarland University, Medical School, Homburg Saar, Germany
    Exp Hematol 33:1257-61. 2005
    ..Fast hematopoietic recovery is critical for the patients' course after hematopoietic stem cell transplantation. It is unknown whether telomere length in hematopoietic stem cells (HSCs) predicts short-term hematopoietic recovery...
  52. ncbi request reprint Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer
    Boris Kubuschok
    Department of Internal Medicine I, University of Saarland Medical School, Homburg Saar, Germany
    Clin Cancer Res 12:1365-72. 2006
    ..In conclusion, a natural T-cell response against muRas proteins that could be exploited for immunostimulatory therapeutic approaches has been shown in a significant proportion of patients with pancreatic cancer...
  53. ncbi request reprint Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell ly
    Christina Nickenig
    Department of Internal Medicine III, Ludwig Maximilians University, Munich Grosshadern, Germany
    Cancer 107:1014-22. 2006
    ..In patients with advanced-stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades...
  54. ncbi request reprint Serological immune response to cancer testis antigens in patients with pancreatic cancer
    Andreas Wadle
    Department of Internal Medicine I, University of Saarland Medical School, Homburg Saar, Germany
    Int J Cancer 119:117-25. 2006
    ..These results indicate that identification of additional tumor antigens by serological screening of tumor cDNA expression libraries by RAYS is a promising goal in pancreatic cancer...
  55. ncbi request reprint The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer
    Inka Seil
    Georg Speyer Haus, Institute for Biomedical Research, Frankfurt, Germany
    Int J Cancer 120:2635-42. 2007
    ....
  56. ncbi request reprint Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma
    Bertram Glass
    Department of Hematology and Oncology, University Hospital of Gottingen, Robert Koch Strasse 40, D 37075 Gottingen, Germany
    Blood 107:3058-64. 2006
    ..9% versus 54.2%). Repetitive HDT with escalated CHOP plus etoposide is feasible and effective treatment of patients with aNHL. DL2 of this therapy is being used in an ongoing phase 3 study...
  57. ncbi request reprint Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with po
    Nobert Schmitz
    Department of Hematology, AK St Georg, Hamburg, Germany
    Cancer 106:136-45. 2006
    ....
  58. ncbi request reprint Low sensitivity of the ki-ras polymerase chain reaction for diagnosing pancreatic cancer from pancreatic juice and bile: a multicenter prospective trial
    Lorenz Trumper
    Department of Internal Medicine I and Department of Internal Medicine II, University of the Saarland, Homburg
    J Clin Oncol 20:4331-7. 2002
    ..A prospective, partially blinded, multicenter diagnostic trial was performed to test the sensitivity and specificity of the ki-ras polymerase chain reaction (PCR) analysis of pancreatic juice and bile specimens...
  59. ncbi request reprint A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing
    Ozlem Tureci
    III Medizinische Klinik und Poliklinik, Johannes Gutenberg Universitat Mainz, D 55131 Mainz, Germany
    Oncogene 21:3879-88. 2002
    ....
  60. ncbi request reprint Differential expression of cancer testis genes in histological subtypes of non-Hodgkin's lymphomas
    Xiaoxun Xie
    Department of Internal Medicine, Saarland University Medical School, D 66421 Homburg Saar, Germany
    Clin Cancer Res 9:167-73. 2003
    ..The purpose of this study was to determine the potentialof cancer testis (CT) antigens as vaccines for non-Hodgkin's lymphomas (NHLs)...
  61. ncbi request reprint Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer
    Axel Mischo
    Department of Internal Medicine I, University of Saarland Medical School, Homburg Saar, Germany
    Int J Cancer 118:696-703. 2006
    ..Our results show that breast carcinomas are among the tumors with the most frequent expression of CT antigens, rendering many patients potential candidates for vaccine trials...
  62. ncbi request reprint B-cell epitopes from the cancer testis antigen NY-ESO-1
    Klaus Dieter Preuss
    Int J Cancer 118:253. 2006
  63. ncbi request reprint Analysis of the antibody repertoire of lymphoma patients
    Shaoming Huang
    Department of Medicine, Saarland University Medical School, 66421 Homburg, Germany
    Cancer Immunol Immunother 51:655-62. 2002
    ..The number of CGA detectable by the classical SEREX approach appears to be limited, and novel strategies are necessary to identify antigens that can serve as a vaccine target in a broad spectrum of NHL patients...
  64. ncbi request reprint Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes
    Frank Neumann
    Med Klinik I, Saarland University Medical School, 66421 Homburg, Germany
    Cancer Immunol Immunother 53:589-99. 2004
    ..In conclusion, p134-148 holds promise as a broadly applicable peptide vaccine for patients with NY-ESO-1-positive neoplasms...
  65. ncbi request reprint Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells
    Frank Neumann
    Medizinische Klinik I, Saarland University Medical School, D 66421 Homburg Saar, Germany
    Blood 106:3105-13. 2005
    ..Thus, p635-649 is the first HOM-TES-14/SCP1-derived epitope to fulfill all prerequisites for use as a peptide vaccine in patients with HOM-TES-14/SCP1-expressing tumors, which is the case in two thirds of peripheral T-cell lymphomas...
  66. ncbi request reprint Identification of antigenic targets of paraproteins by expression cloning does not support a causal role of chronic antigenic stimulation in the pathogenesis of multiple myeloma and MGUS
    Klaus Dieter Preuss
    Klinik fur Innere Medizin I, Saarland University Medical School, Homburg Saar, Germany
    Int J Cancer 121:459-61. 2007
    ....
  67. ncbi request reprint Notch signaling
    Sandra Hess
    J Neurosurg 107:1060-1; author reply 1061-2. 2007
  68. ncbi request reprint Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia
    Rudiger Hehlmann
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Wiesbadener Strasse 7 11, 63805 Mannheim, Germany
    Blood 109:4686-92. 2007
    ..032). The general recommendation of HSCT as first-line treatment option in chronic phase CML can no longer be maintained. It should be replaced by a trial with modern drug treatment first...
  69. ncbi request reprint Mitofilin and titin as target antigens in melanoma-associated retinopathy
    Claudia Pföhler
    Department of Dermatology, Saarland University Medical School, Homburg Saar, Germany
    Int J Cancer 120:788-95. 2007
    ....
  70. doi request reprint First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
    Anton Hagenbeek
    University Medical Center Utrecht, Department of Hematology, Utrecht, The Netherlands
    Blood 111:5486-95. 2008
    ..9 months at a median/maximum follow-up of 9.2/38.6 months. Ofatumumab is currently being evaluated in patients with rituximab-refractory FL. This trial was registered at www.clinicaltrials.gov as #NCT00092274...
  71. ncbi request reprint Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein
    Stefan Bauer
    Medical Department I, Universitat des Saarlandes, Homburg Saar, Germany
    J Immunol 172:3930-9. 2004
    ..These data warrant transfer of the anti-FAP-TNF immunocytokine into clinical trials for the treatment of FAP-positive tumors...
  72. ncbi request reprint Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis
    Boris Kubuschok
    Department of Internal Medicine I, University of Saarland Medical School, Homburg Saar, Germany
    Int J Cancer 109:568-75. 2004
    ..SCP-1 and GAGE represent promising candidates for vaccine development in pancreatic carcinoma. Whether SCP-1 and GAGE expression identify cases of chronic pancreatitis with a high risk of malignant transformation remains to be shown...
  73. doi request reprint Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study
    Dieter Kube
    Department of Hematology and Oncology and Pharmacology, Medical School of the Georg August University, Gottingen, Germany
    Clin Cancer Res 14:3777-84. 2008
    ..IL-10 was chosen because immune alterations are a major risk factor for NHL, and IL-10 is a cytokine involved in inflammatory processes associated with clinical outcome...
  74. ncbi request reprint Serological identification of breast cancer-related antigens from a Saccharomyces cerevisiae surface display library
    Andreas Wadle
    I Med Klinik, Saarland University Medical School, Homburg Saar, Germany
    Int J Cancer 117:104-13. 2005
    ..The small breast epithelial mucin is present to a large extent in a membrane bound format and might be used for tumor targeting strategies...
  75. doi request reprint Effects of physical exercise on myocardial telomere-regulating proteins, survival pathways, and apoptosis
    Christian Werner
    Klinik fur Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    J Am Coll Cardiol 52:470-82. 2008
    ..The purpose of this study was to study the underlying molecular mechanisms of the protective cardiac effects of physical exercise...
  76. ncbi request reprint Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach
    Martin Schlapschy
    Lehrstuhl fur Biologische Chemie, Technische Universitat Munchen, 85350 Freising Weihenstephan and CR MP Saarland University Medical School, 66421 Homburg Saar, Germany
    Protein Eng Des Sel 17:847-60. 2004
    ..The combination of random mutagenesis and colony filter screening assay that was successfully applied here should be generally useful as a method for the rapid functional optimization of humanized antibody fragments...